ArtJen Announces Major Clinical Trial Of Its Patented Weight Loss Product FBCx

Main Category: Obesity / Weight Loss / Fitness
Also Included In: Nutrition / Diet;  Clinical Trials / Drug Trials
Article Date: 20 Sep 2007 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

ArtJen Complexus Holdings Corp. (http://www.fbcx.com) announced that, following the results of their clinical trial with obese type 2 diabetics and an animal study at the National Institutes of Health, FBCx is being studied by a major US west-coast university medical center. The largest study to date on the patented all natural soluble fiber that binds dietary fat will involve overweight but not obese individuals.

"Our earlier study with obese, type 2 diabetics demonstrated significant weight loss when adjusted for changes in diet." said FBCx co-inventor, Dr. Catherine Jen. "It's time to look at the non-obese population segment that would benefit from losing 10-25 pounds."

"We expect this study will show FBCx to be an easy and effective aid for losing weight and for lowering elevated levels of blood fats," continued FBCx co-inventor, Dr. Joseph Artiss.

Previous FBCx study findings include:

-- Effective at reducing and/or maintaining body weight in patients with type 2 diabetes.

-- Lowered both triglyceride and LDL (bad) cholesterol levels in patients who began the study with elevated triglyceride levels.

-- Blood work findings indicate an insulin sensitivity increase and therefore a possible delay in the need to institute or the intensity of insulin therapy in type 2 diabetics.

-- FBCx was shown to bind and remove 9 times its own weight in dietary fat, essentially preventing 80 calories from being absorbed per tablet.

-- FBCx appears to preferentially bind saturated over unsaturated dietary fats.

-- FBCx produced no adverse side effects.

These findings and others have lead to FBCx being referred to as the "miracle weight loss" pill in media reports and by renowned members of the medical profession.

"We are so convinced of the efficacy of FBCx that we sought out and funded this major study ourselves," said Dr. Artiss.

"I have spent my entire career studying obesity. FBCx works where most others have failed to live up to their hype," stated Dr. Jen.

FBCx co-inventors are Associate Professor of Pathology Joseph Artiss, Ph.D., FACB and K-L Catherine Jen, Ph.D., Professor and Chair of Nutrition and Food Science, both of Wayne State University in Detroit, Michigan.

Six tablets daily are capable of removing 50-60% of the calories from a typical North American diet.

ArtJen Complexus Holdings Corp.
http://www.fbcx.com